Viking Therapeutics: BTIG Confirms Buy Recommendation with Approximately 267% Price Potential!
Reading Time: 2 minutes
In the current press releases from February 2026, Viking Therapeutics (VKTX) presents itself from a corporate perspective as an extremely robust and dynamically growing biotech company, distinguished by significant clinical milestones. During the announcement of the financial results for the fourth quarter of 2025 on February 11, 2026, CEO Brian Lian emphasized the exceptional past year and the rapid development of its obesity portfolio. The company is aggressively advancing its dual GLP-1/GIP receptor agonist VK2735: While the Phase 3 study "VANQUISH-1"...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
